Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Renee J. Perdok"'
1
Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial
Autor: Eric H. Sasso, Mary A. Cifaldi, John R. Medich, Philip J. Mease, Renee J. Perdok, Dafna D. Gladman
Publikováno v: Annals of the Rheumatic Diseases. 66:163-168
Objective: To evaluate the effects of adalimumab on patient-reported outcomes of joint- and skin-related functional impairment, health-related quality of life (HRQOL), fatigue, and pain in patients with psoriatic arthritis (PsA). Methods: Patients wi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfc22057f50cfee1b91f278afc9603b6
https://doi.org/10.1136/ard.2006.057901
Zobrazit plný text záznamu
2
Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial
Autor: Alexa B. Kimball, Joaquin Mario Valdes, Alan Menter, Renee J. Perdok, Richard G. Langley, Kenneth B. Gordon
Publikováno v: Journal of the American Academy of Dermatology. 64(2)
Background ABT-874, an anti–interleukin-12 and -23 antibody, was previously shown to be significantly more effective compared with placebo during a 12-week phase II study of psoriasis. We report here safety and efficacy data of ABT-874 during subse
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ac9035a532ef60181e8d5c0bd700407
https://pubmed.ncbi.nlm.nih.gov/21145618
Zobrazit plný text záznamu
3
Adalimumab for long-term treatment of psoriatic arthritis : 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
Autor: P. J. Mease, Glen T D Thomson, John R. Medich, C. Birbara, Robert L. Wong, F. Van den Bosch, F Wellborne, Renee J. Perdok, Christopher T. Ritchlin, Dafna D. Gladman, P Ory, John T. Sharp
Publikováno v: ANNALS OF THE RHEUMATIC DISEASES
Annals of the Rheumatic Diseases
Objective:To evaluate the long-term effectiveness and tolerability of adalimumab in the treatment of psoriatic arthritis (PsA).Methods:Patients with PsA who completed a 24-week, double-blind study of adalimumab versus placebo were eligible to enroll
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33a0d5cc04a902fbc4fc4d3af791797a
https://hdl.handle.net/1854/LU-8730341
Zobrazit plný text záznamu
4
Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy
Autor: Mark C, Genovese, Philip J, Mease, Glen T D, Thomson, Alan J, Kivitz, Renee J, Perdok, Mark A, Weinberg, John, Medich, Eric H, Sasso
Publikováno v: The Journal of rheumatology. 34(5)
To demonstrate the safety and efficacy of adalimumab for the treatment of active psoriatic arthritis (PsA) in patients with an inadequate response to disease modifying antirheumatic drugs (DMARD).In a placebo controlled, double-blind, randomized, mul
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::722a97e56b4c73a7efda88a7bf0ae2f7
https://pubmed.ncbi.nlm.nih.gov/17444593
Zobrazit plný text záznamu
5
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial
Autor: Christopher T. Ritchlin, Peter A. Ory, Philip J. Mease, Ernest Choy, Dafna D. Gladman, Eric H. Sasso, John T. Sharp, Renee J. Perdok
Publikováno v: Arthritis and rheumatism. 56(2)
Objective To evaluate the efficacy and safety of treatment with adalimumab, a fully human anti–tumor necrosis factor (anti-TNF) monoclonal antibody, over 48 weeks in patients with moderate to severe psoriatic arthritis (PsA). Methods Patients who c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17e87f7dd242115884aeafd78f05dee4
https://pubmed.ncbi.nlm.nih.gov/17265483
Zobrazit plný text záznamu
6
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial
Autor: Serge Steinfeld, Eric Ruderman, Peter A. Ory, Dafna D. Gladman, John T. Sharp, Philip J. Mease, Renee J. Perdok, Christopher T. Ritchlin, M A Weinberg, Ernest Choy
Publikováno v: Arthritis and rheumatism. 52(10)
Objective Adalimumab, a fully human, anti–tumor necrosis factor monoclonal antibody, was evaluated for its safety and efficacy compared with placebo in the treatment of active psoriatic arthritis (PsA). Methods Patients with moderately to severely
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1825dd3642707dcd79f26ed46cc3b114
https://pubmed.ncbi.nlm.nih.gov/16200601
Zobrazit plný text záznamu
8
Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT
Autor: Christopher T. Ritchlin, Eric H. Sasso, Renee J. Perdok, Philip J. Mease, Dafna D. Gladman, Ernest Choy
Publikováno v: Arthritis Research & Therapy
Introduction To identify independent predictors of radiographic progression in psoriatic arthritis (PsA) for patients treated with adalimumab or placebo in the Adalimumab Effectiveness in PsA Trial (ADEPT). Methods Univariate analyses and multivariat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::887edf776520028e8ddd7d582bf93665
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje